fig2

Figure 2. Management of endocrine-resistant luminal ABC patients. Similar to the endocrine-sensitive scenario, endocrine-resistant with or without targeted therapy remains a core treatment approach. Prior lines of therapy should be used before initiating CT. Preferred therapeutic options are represented for women harboring specific gene mutations or without identified mutations. All therapies included are evidence-based unless otherwise noted. AI: Aromatase inhibitor; BRCA: breast cancer gene; CDK4/6i: cyclin-dependent kinase 4/6 inhibitors; CT: chemotherapy; ERS1: estrogen receptor 1; ET: endocrine therapy; ERBB2: v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2; mut: mutated; PD: progressive disease; PFS: progression-free survival; SG: Sacituzumab govitecan; T-DXd: trastuzumab deruxtecan; wt: wild type; ABC: advanced breast cancer.